Such dynamic biomarkers in the early treatment phase could complement or even outperform static pre-treatment biomarkers (e.g., PD-L1 expression in primary tumor tissue), as they would reflect the complex mechanisms behind immune response more accurately45. This evidence concerns the gene CD274 and neoplasm.